Neurogene Inc. financial data

Symbol
NGNE on Nasdaq
Industry
Pharmaceutical Preparations
Location
535 W 24 Th Street, 5 Th Floor, New York, NY
Fiscal year end
December 31
Former names
Neoleukin Therapeutics, Inc. (to 12/6/2023), AQUINOX PHARMACEUTICALS, INC (to 8/12/2019), AQUINOX PHARMACEUTICALS (USA) INC (to 12/24/2013)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.16K % -7.89%
Debt-to-equity 17.1 %
Return On Equity -17.9 % -134%
Return On Assets -15.3 % +66.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13M shares -70.5%
Common Stock, Shares, Outstanding 13M shares -70.5%
Entity Public Float 33.4M USD -7.62%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 16.9M shares +3712%
Weighted Average Number of Shares Outstanding, Diluted 16.9M shares +3712%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 925K USD
Research and Development Expense 53.1M USD +14.3%
General and Administrative Expense 16.7M USD +275%
Operating Income (Loss) -68.9M USD -35.3%
Nonoperating Income (Expense) -24K USD +36.8%
Net Income (Loss) Attributable to Parent -26.3M USD +45.5%
Earnings Per Share, Basic 25.3 USD/shares +95.9%
Earnings Per Share, Diluted 0.43 USD/shares +95.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 111M USD +257%
Other Assets, Current 1.53M USD -10.9%
Assets, Current 159M USD +90%
Property, Plant and Equipment, Net 16.1M USD +2763%
Operating Lease, Right-of-Use Asset 3.38M USD -63%
Other Assets, Noncurrent 794K USD +50.1%
Assets 180M USD +91.3%
Accounts Payable, Current 1.72M USD
Employee-related Liabilities, Current 2.14M USD
Accrued Liabilities, Current 7.14M USD
Liabilities, Current 13.1M USD +168%
Operating Lease, Liability, Noncurrent 10.9M USD +14.4%
Other Liabilities, Noncurrent 51K USD
Liabilities 24.8M USD +71.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -223M USD +52.4%
Stockholders' Equity Attributable to Parent 155M USD
Liabilities and Equity 180M USD +91.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.7M USD -59.7%
Net Cash Provided by (Used in) Financing Activities -6.52M USD -6197%
Net Cash Provided by (Used in) Investing Activities 29.9M USD
Common Stock, Shares Authorized 450M shares +350%
Common Stock, Shares, Issued 13M shares -70.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.76M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 111M USD +88.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3K USD +50%
Deferred Tax Assets, Valuation Allowance 98.9M USD +159%
Deferred Tax Assets, Gross 99.9M USD +154%
Operating Lease, Liability 13.7M USD
Payments to Acquire Property, Plant, and Equipment 65K USD +124%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.2M USD +65.5%
Lessee, Operating Lease, Liability, to be Paid 16.8M USD
Property, Plant and Equipment, Gross 25.7M USD
Operating Lease, Liability, Current 2.77M USD +85.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.7M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.99M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.24M USD
Deferred Tax Assets, Operating Loss Carryforwards 60.3M USD +139%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares +900%
Unrecognized Tax Benefits 2.61M USD +136%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.29M USD
Operating Lease, Payments 1.31M USD
Additional Paid in Capital 378M USD -31%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 800K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 949K USD -18.5%
Share-based Payment Arrangement, Expense 4.1M USD +503%
Interest Expense 3K USD +50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%